A5074656080- Neuroendocrine Tumor Research Advances
- Neuroblastoma Research and Treatments
- Lung Cancer Research Studies
- Cancer Risks and Factors
- Chronic Lymphocytic Leukemia Research
- HER2/EGFR in Cancer Research
- Breast Cancer Treatment Studies
- Ubiquitin and proteasome pathways
- Autoimmune and Inflammatory Disorders
- Actinomycetales infections and treatment
- Peroxisome Proliferator-Activated Receptors
- Liver Disease Diagnosis and Treatment
- Iron Metabolism and Disorders
- Hemoglobinopathies and Related Disorders
- Metastasis and carcinoma case studies
- Colorectal Cancer Treatments and Studies
- CNS Lymphoma Diagnosis and Treatment
- Gastric Cancer Management and Outcomes
- NF-κB Signaling Pathways
- Radiomics and Machine Learning in Medical Imaging
- Cancer Research and Treatments
- Pancreatic and Hepatic Oncology Research
- Lymphoma Diagnosis and Treatment
- Nanoplatforms for cancer theranostics
- Erythrocyte Function and Pathophysiology
UCLouvain Saint-Louis Brussels
2024
Saint Louis University
2023
Rush University Medical Center
2020-2022
University Hospital Heidelberg
2017-2018
University Medical Center of the Johannes Gutenberg University Mainz
2017-2018
Johannes Gutenberg University Mainz
2008-2018
Heidelberg University
2017-2018
University of Illinois Chicago
2017-2018
Karlsruhe Institute of Technology
2017
<h3>Importance</h3> Despite the benefit of peptide receptor radionuclide therapy (PRRT) for patients with well-differentiated neuroendocrine tumors (WD NETs), no clinical metric to anticipate from individual has been previously defined. <h3>Objective</h3> To assess whether prognostic ability score (CS) could be validated in an external cohort WD NETs. <h3>Design, Setting, and Participants</h3> This multicenter study's analysis included NETs who were under consideration lutetium-177...
TPS205 Background: ECF/X (epirubicin + cisplatin 5-FU or capecitabine (X)) is a preferred GC chemotherapy (CT) regimen. Survival of HER2+ metastatic prolonged by trastuzumab when administered with CF/X (VanCutsem, ASCO 2009). Lapatinib inhibits both EGFR1 and HER2, active in gastric cell lines, has shown clinical activity uncontrolled phase II trials. A III trial lapatinib X oxaliplatin (FISH) ongoing. Additional unaddressed questions include the efficacy safety its patients (pts) discordant...
We developed a clinical score (CS) at Vanderbilt Ingram Cancer Center (VICC) that we hoped would predict outcomes for patients with progressive well-differentiated neuroendocrine tumors (NETs) receiving therapy Lutetium-177 (177Lu)-DOTATATE. Patients under consideration 177Lu-DOTATATE between March 1, 2016 and 17, 2020 VICC were assigned CS prospectively. The included 5 categories: available treatments tumor type outside of 177Lu-DOTATATE, prior systemic treatments, patient symptoms, burden...
Abstract Background:Aberrant signaling through HER2 and other members of the HER family has been identified as mediator endocrine resistance in estrogen receptor alpha (ERα) positive breast cancer. On hand, ERα co-expression shown to attenuate efficiency anti-HER2 targeted therapies. These findings indicate that synergize allow cancer cells escape from both anti-ERα anti-HER2-targeted Rationally designed clinical trials combine therapy with agents interfere HER2/ERα cross-talk have...
Gestational breast cancer (GBC) is the most common form of invasive in pregnancy and has unique challenges both staging treatment given dual goal appropriate management minimising risk fetal toxicity. A 38-year-old woman with no significant medical history 21 weeks pregnant presented a palpable right mass. She was diagnosed human epidermal growth factor receptor 2-positive infiltrating ductal carcinoma advanced disease. The patient underwent treatment; however, unfortunately, she passed away...
Hintergrund: Der seltene, niedrig maligne SPT betrifft überwiegend junge Frauen. Das Langzeitüberleben nach Resektion liegt bei ca. 95 %. In Ausnahmefällen findet sich das solid pseudopapilläre Karzinom (SPC) mit eindeutigen Malignitätskriterien. Inoperable Lebermetastasen können RFA, TACE oder Chemotherapie behandelt werden. Methoden: Retrospektive Analyse des chirurgischen Vorgehens, der Immunhistochemie und klinischen Verlaufs von fünf Patientinnen (1998 – 2007). Ergebnis: mittlere Alter...
Abstract Background: Early-stage breast cancer is a common condition with significant effects on health, both as result of treatment and underlying conditions. Breast has been associated obesity, weight gain, diabetes. Little known about changes in after diagnoses based baseline weight. Additionally, change may differ due to treatments, such chemotherapy or hormone therapy. Methods: A retrospective study was conducted using deidentified electronic medical records data from national health...
Classical Hodgkin Lymphoma (cHL) is a B-cell derived lymphoma with excellent cure rates, however poor functional status or co-morbid conditions limit treatment options. Brentuximab vedotin (BV), CD30 antibody drug conjugate, has an expanding role in cHL treatment. A 53-year-old man multiple co-morbidities including end stage renal disease (ESRD) presenting pancytopenia was found to have cHL. Not candidate for intensive chemotherapy, he safely maintained on intermittent BV three years....
363 Background: Despite the benefit of PRRT for patients with WD NETs, questions remain regarding sequencing and optimal patient selection treatment. We developed a CS at Vanderbilt Ingram Cancer Center (VICC) that we hoped would predict outcomes NETs receiving PRRT. Methods: Patients progressive (N = 146) under consideration Lu 177-dotatate between 3/1/2016-3/17/2020 VICC 122) Rush Medical (RMC) 24) were scored. The included 5 categories: available non-PRRT treatments tumor type, prior...
Einleitung: B cell leukemia-3 (bcl-3) – ursprünglich als Protoonkogen identifiziert kodiert für ein nukleäres Protein der IkB-Familie, das sowohl Inhibitor auch Co-Aktivator beiden NF-κB Untereinheiten p50 oder p52 wirken kann. Aufgrund Fähigkeit die NF-κB-Aktivität zu modulieren, ist anzunehmen, dass Bcl-3 zentraler Regulator inflammatorischer Prozesse ist. Die Bedeutung von bei Regulation in Leber unverstanden. Wir nehmen an, Entzündung im Rahmen nicht-alkoholischen Steatohepatitis (NASH)...
Foltys, D1; Hinkelmann, A2; Heumann, A1; Ruth, I1; Heise, M1; Schad, Schneider, J1; Bender, K1; Mauer, D3; Otto, G1 Author Information
Abstract Background:Oncogene-induced senescence is considered as a barrier to tumor progression that arrests cells at risk for malignant transformation. Nevertheless, numerous findings demonstrate senescent may also have the opposite function and promote through release of multiple factors called senescence-associated secretory phenotype or secretome. It likely composition physiological consequences mediated by secretome are dependent on oncogenes trigger program. Breast cancer represents...
Actinomyces are gram positive, filamentous rods part of the normal oropharyngeal and gastrointestinal flora rarely become infectious. Infections slowly progressive, commonly occur in orocervicofacial region, do not typically resolve without antibiotics. We present a patient with invasive esophageal presenting malabsorption. A 61 year-old female history diabetes chronic kidney disease stage IV presented fever weakness. She was treated for S. pyogenes bacteremia, but her management complicated...
Abstract Accurate diagnostic biomarker testing, including estrogen receptor (ER), progesterone (PR), and human epidermal growth factor 2 (Her2) expression profile, is crucial to appropriate management decisions in breast cancer. Receptor status testing typically performed on the initial core needle biopsy (CNB) surgical specimen (SS). The rate of concordance between CNB SS unclear as impact this has clinical decision making. current guidelines retesting are vague, which results individual...
4109 Background: Questions remain regarding when to sequence PRRT and how categorize pts being considered for the treatment (tx). We previously developed a CS (comprised of 5 categories: available non-PRRT tx tumor type, prior systemic tx, pt symptoms, burden in critical organs peritoneal carcinomatosis presence) at Vanderbilt Ingram Cancer Center (VICC) help answer these questions demonstrated score be associated with progression-free survival (PFS) receiving PRRT. Herein, we present...